Journal of the Korean Association of Oral and Maxillofacial Surgeons

The Korean Association of Oral and Maxillofacial Surgeons (대한구강악안면외과학회)
권호 표지
DOI QR코드

DOI QR Code

Anti-epidermal growth factor receptor (EGFR) monoclonal antibody and DNA topoisomerase inhibitor reduce growth of salivary adenoid cystic carcinoma in a murine model

항-표피성장인자수용체 단클론항체와 DNA 토포이소머라제 억제제에 의한 마우스 모델에서의 타액선 선낭암종 성장 억제

  • Park, Young-Wook (Departments of Oral and Maxillofacial Surgery, College of Dentistry, Gangneung-Wonju National University) ;
  • Lee, Hee-Su (Departments of Oral Anatomy, College of Dentistry, College of Dentistry, Gangneung-Wonju National University)
  • 박영욱 (강릉원주대학교 치과대학 구강악안면외과학교실) ;
  • 이희수 (강릉원주대학교 치과대학 구강해부학교실)
  • Received : 2010.05.20
  • Accepted : 2010.06.10
  • Published : 2010.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Introduction: Epidermal growth factor receptor (EGFR) is expressed in human epithelial tumors including salivary cancers, and known to be correlated with tumor progression and poor clinical courses in some epithelial tumors. In this study, we determined the therapeutic effect of the anti-EGFR monoclonal antibody Erbitux (C225, cetuximab) in combination with the DNA topoisomerase I inhibitor irinotecan (CPT-11) on human salivary adenoid cystic carcinoma (SACC) cells growing in nude mice. Materials and Methods: At first, immunocytochemical analysis for the expression of EGFR and phosphorylated EGFR (pEGFR) on a human salivary ACC cell line (ACC3). To determine the in vivo effects of Erbitux and CPT-11, nude mice with orthotopic parotid tumors were randomized to receive intraperitoneal Erbitux (1 mg) two times per week, intraperitoneal Irinotecan (50 mg/kg) once per week, Erbitux plus CPT-11, or placebo. (control) Tumor volume and weight were measured. And mechanisms of in vivo activity of Erbitux and/or CPT-11 were determined by immunohistochemical/ immunofluorescent analyses. Results: Immunocytochemical staining of ACC3 demonstrated that EGFR was expressed and phosphorylated. CPT-11 inhibited ACC tumor growth in nude mice. Tumors of mice treated with CPT-11 and CPT-11 plus Erbitux exhibited increased tumor cell apoptosis and decreased microvessel density, which correlated with a decrease in the tumor volume in nude mice. But, CPT-11 seems not to be synergistic with Erbitux in our ACC3 model system. Conclusion: These results suggest that anti-EGFR monoclonal antibody and the DNA topoisomerase I inhibitor will be effective in the treatment of recurred or metastatic lesions of salivary ACC.

Keywords

References

  1. Licitra L, Locati LD, Bossi P, Cantu G. Head and neck tumors other than squamous cell carcinoma. Curr Opin Oncol 2004; 236-41. https://doi.org/10.1097/00001622-200405000-00008
  2. Jones AS, Hamilton JW, Rowley H, Husband D, Helliwell TR. Adenoid cystic carcinoma of the head and neck. Clin Otolaryngol 1997;22:434-43. https://doi.org/10.1046/j.1365-2273.1997.00041.x
  3. Laurie SA, Licitra L. Systemic therapy in the palliative management of advanced salivary grand cancers. J Clin Oncol 2006; 24:2673-8. https://doi.org/10.1200/JCO.2005.05.3025
  4. Airoldi M, Cortesina G, Giordano C, Pedani F, Cavalot A, Marcato P, et al. Update and perspectives on non-surgical treatment of salivary gland malignancies. Acta Otorhinolaryngol Ital 2003;23:368-76.
  5. Kuwai T, Nakamura T, Sasaki T, Kim SJ, Fan D, Villares GJ, et al. Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors. Neoplasia 2008;10:489-500. https://doi.org/10.1593/neo.08200
  6. Herbst RS, Hong WK. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Semin Oncol 2002; 29(5 Suppl 14):18-30. https://doi.org/10.1053/sonc.2002.35644
  7. Park YW, Kim JH. Immunohistochemical assays for the expression of epidermal growth factor-signaling proteins in adenoid cystic carcinoma of human salivary glands. J Korean Assoc Maxillofac Plast Reconstr Surg 2006;28:499-510.
  8. Younes MN, Park YW, Yazici YD, Gu M, Santillan AA, Nong X, et al. Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model. Mol Cancer Ther 2006;5:2696-705. https://doi.org/10.1158/1535-7163.MCT-05-0228
  9. Agulnik M, Cohen EW, Cohen RB, Chen EX, Vokes EE, Hotte SJ, et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 2007;25:3978-84. https://doi.org/10.1200/JCO.2007.11.8612
  10. Dahse R, Driemel O, Schwarz S, Dahse J, Kromeyer-Hauschild K, Berndt A, et al. Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas. Br J Cancer 2009;100:623-5. https://doi.org/10.1038/sj.bjc.6604875
  11. Dahse R, Driemel O, Schwarz S, Kromeyer-Hauschild K, Berndt A, Kosmehl H, et al. KRAS status and epidermal growth factor receptor expression as determinants for anti-EGFR therapies in salivary gland carcinomas. Oral Oncol 2009;45:826-9. https://doi.org/10.1016/j.oraloncology.2009.01.013
  12. Rothenberg ML. Topoisomerase I inhibitors: review and update. Ann Oncol 1997;8:837-55. https://doi.org/10.1023/A:1008270717294
  13. Rivory LP. Irinotecan (CPT-11): a brief overview. Clin Exp Pharmacol Physiol 1996;23:1000-4. https://doi.org/10.1111/j.1440-1681.1996.tb01158.x
  14. Larsen AK, Gobert C. DNA topoisomerase I in oncology: Dr. Jekyll or Mr. Hyde? Pathol Oncol Res 1999;5:171-8. https://doi.org/10.1053/paor.1999.0209
  15. Saijo N. Preclinical and clinical trials of topoisomerase inhibitors. Ann N Y Acad Sci 2000;922:92-9.
  16. Friedman HS, Keir ST, Houghton PJ. The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors. Cancer 2003;97(9 Suppl):2359-62. https://doi.org/10.1002/cncr.11305
  17. Rothenberg ML, Cox JV, DeVore RF, Hainsworth JD, Pazdur R, Rivkin SE, et al. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 1999;85:786-95. https://doi.org/10.1002/(SICI)1097-0142(19990215)85:4<786::AID-CNCR5>3.0.CO;2-9
  18. Ross PJ, Teoh EM, A'hern RP, Rhys-Evans PH, Harrington KJ, Nutting CM, et al. Epirubicin, cisplatin and protracted venous infusion 5-Fluorouracil chemotherapy for advanced salivary adenoid cystic carcinoma. Clin Oncol (R Coll Radiol) 2009;21(4): 311-4. https://doi.org/10.1016/j.clon.2008.12.009
  19. Park YW, Chung SH. An experimental study for establishment of orthotopic salivary tumor models in mice. J Korean Assoc Oral Maxillofac Surg 2007;33:81-93.
  20. Park YW. Targeted molecular therapy in a murine model of oral squamous cell carcinoma with an epidermal growth factor receptor inhibitor. J Korean Assoc Maxillofac Plast Reconstr Surg 2009;31:8-17.
  21. Raynal C, Pascussi JM, Leguelinel G, Breuker C, Kantar J, Lallemant B, et al. Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation. Mol Cancer 2010; 9:46.
  22. Louvet C, Andre T, Gamelin E, Garcia ML, Saavedra A, Lenaers G, et al. A phase I-II, dose-escalating trial of ZD9331 in combination with irinotecan (CPT-11) in previously pretreated metastatic colorectal cancer patients. Bull Cancer 2004;91:279-84.
  23. Kokawa K, Nishimura R, Fujii T, Umesaki N. Neoadjuvant chemotherapy with irinotecan and mitomycin-C for locally advanced squamous cell carcinoma of the uterine cervix. Anticancer Res 2007;27:2721-7.
  24. Mrozek E, Kolesar J, Young D, Allen J, Villalona-Calero M, Shapiro CL. Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC). Ann Oncol 2008;19:1417-22. https://doi.org/10.1093/annonc/mdn154
  25. Argiris A, Buchanan A, Brockstein B, Kolesar J, Ghebremichael M, Pins M, et al. Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group. Cancer 2009;115:4504-13. https://doi.org/10.1002/cncr.24528
  26. Bastos BR, Hatoum GF, Walker GR, Tolba K, Takita C, Gomez J, et al. Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung cell lung cancer. J Thorac Oncol 2010;5(4):533-9. https://doi.org/10.1097/JTO.0b013e3181ce3e00
  27. Ciardiello F, Bianco R, Damiano V, de Lorenzo S, Pepe S, de Placido S, et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 1999;5:909-16.
  28. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999;59:1935-40.
  29. Buchsbaum DJ, Bonner JA, Grizzle WE, Stackhouse MA, Carpenter M, Hicklin DJ, et al. Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int J Radiat Oncol Biol Phys 2002; 54:1180-93. https://doi.org/10.1016/S0360-3016(02)03788-4
  30. Bonner JA, Giralt J, Harari PM, Cohen R, Jones C, Sur RK, et al. Prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high does radiation therapy with and without cetuximab. J Clin Oncol 2004;22:5507. https://doi.org/10.1200/jco.2004.22.14_suppl.5507
  31. Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 2004;11:689-708. https://doi.org/10.1677/erc.1.00600
  32. Gill GN, Kawamoto T, Cochet C, Le A, Sato JD, Masui H, et al. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem 1984;259:7755-60.
  33. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002;8:994-1003.
  34. Koizumi F, Kanzawa F, Ueda Y, Koh Y, Tsukiyama S, Taguchi F, et al. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells. Int J Cancer 2004;108:464-72. https://doi.org/10.1002/ijc.11539
  35. Kim S, Prichard CN, Younes MN, Yazici YD, Jasser SA, Bekele BN, et al. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin Cancer Res 2006;12:600-7. https://doi.org/10.1158/1078-0432.CCR-05-1325